Abstract: Objective To investigate the treatment and factors influencing quality of life （QOL） in patients with chronic myelogenous leukemia （CML） in Guangyuan, Sichuan Province. Methods CML patients who were re-examined in Guangyuan Central Hospital, Guangyuan Hospital of Traditional Chinese Medicine and Guangyuan Tumor Hospital from 2015 to 2018 were enrolled in this study by using convenient sampling method. Questionnaire survey was conducted using clinical data questionnaire and leukemia QOL assessment. Univariate and multivariate logistic regressions were used to analyze factors influencing QOL. Results A total of 185 patients with CML were included in the survey, with an average age of （41.62 ± 15.47） years, including 98 （52.97%） males and 87 （47.03%） females. Among the 185 patients, 94 （50.81%） patients were treated with imatinib, 57 （30.81%） with alpha-interferon combined with cytarabine, and 34 （18.38%） with hydroxycarbamide monotherapy. The overall QOL score of CML patients was （122.47 ± 14.43）, with a score rate of （65.37 ± 6.25）%. The social/family dimension scored the highest （76.35 ± 5.17）% and the function module scored the lowest （55.87 ± 5.48）%. In the multivariate linear regression model, that patients with younger age, without concomitant diseases, with medical insurance, higher average monthly family income, higher hemoglobin, higher red blood cell count, and treated with imatinib had higher QOL （standard partial regression coefficients： 0.358, 0.765, 0.546, 0.456, 0.469, 0.462, and 0.486, respectively）. Conclusion The QOL in patients with CML in Guangyuan City, Sichuan Province was not high. It is suggested to use imatinib therapy, interferon-alpha combined with cytidine and hydroxyurea as the main clinical treatments to improve the QOL in patients with CML.

Key words: Chronic myelogenous leukemia, Treatment, Quality of life, Influencing factors